Home > Insider Trading > Filing (0001209191-20-004148)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Biosciences Inc.	PCRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204788	M David Stack	C/O Pacira Biosciences, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054	Ceo And Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-01-15	25,000	$10.81	26,208	No	4	M	Indirect	By LCK Investment LLC
Common Stock	Disposition	2020-01-15	23,025	$42.61	3,183	No	4	S	Indirect	By LCK Investment LLC
Common Stock	Disposition	2020-01-15	1,975	$43.48	1,208	No	4	S	Indirect	By LCK Investment LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By LCK Investment LLC
No	4	S	Indirect	By LCK Investment LLC
No	4	S	Indirect	By LCK Investment LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-01-15	25,000	$0.00	25,000	$10.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
243,129		2022-06-05	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	162,478	Direct
Common Stock	18,596	Indirect	By Stack Schroon Mohawk FLP

Footnotes

The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Mr. Stack is the general partner of Stack Schroon Mohawk FLP. Mr. Stack and his wife are the owners of LCK Investment LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.340 to $43.330, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.395 to $43.570, inclusive.
Includes 179 shares of common stock acquired under the issuer's employee stock purchase plan in December 2019.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
Reflects the transfer of stock options to purchase 20,541 shares of common stock previously held indirectly by the reporting person through LCK Investment LLC to the reporting person directly.